congresses-banner

The content contained is subject

PublicationView

Poster
Dato-DXd
ISPOR 2024 | May 5-8, 2024
Breast Cancer
Estimating meaningful change thresholds for EORTC scales in a phase 3 trial in participants with inoperable or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
Yanyan Zhu
Poster
Pexidartinib
ISPOR 2024 | May 5-8, 2024
Other/Multi
Health-related quality of life from a phase 4 global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib
Jayesh Desai
Poster
Other/Multi
ISPOR 2024 | May 5-8, 2024
Breast Cancer
Healthcare resource use and costs of care in HR+/HER2- metastatic breast cancer: A retrospective US claims data study
Simon M. Collin
Poster
T-DXd
ISPOR 2024 | May 5-8, 2024
Gastric Cancer
Perceptions, experiences, and behaviors of patients and their caregivers with gastric and gastroesophageal junction cancer treated with or without trastuzumab deruxtecan in the United States
Mackenzie Henderson
Poster
Pexidartinib
ISPOR 2024 | May 5-8, 2024
Other/Multi
Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor (TGCT)
Dong Dai

footer